Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2019

View Archived Issues

New insights into old Fountain of Youth

Preclearance boosts immunotherapy in pancreatic cancer

New vaccine protects nonhuman primates against equine encephalitis viruses

Preclinical evaluation of enzymatically cleavable lipoglycopeptides for pulmonary MRSA

FDA clears Syndax's IND for phase I/II trial of SNDX-5613 for relapsed/refractory acute leukemias

First patient dosed in phase II study of KD-025 in cutaneous systemic sclerosis

Researchers develop CRISPR/Cas9 hemophilia A murine model

Guangdong Newopp Biopharmaceuticals presents new arginase inhibitors

Chiesi discovers Rho kinase inhibitors

New PD-1/PD-L1 interaction inhibitors described by Yangtze River, Shanghai Haiyan

Chengdu Huajian Future Technology patents IDO-1 inhibitors

New catalytic system allows selective cancer cell targeting

Roche describes new hepatitis B virus cccDNA formation inhibitors

Myovant Sciences presents phase II data on MVT-602 in premenopausal women

CB2 receptor PET radiotracer [11C]MDTC evaluated in first-in-human study

Equillium initiates phase Ib trial of itolizumab in uncontrolled moderate to severe asthma

Transgene gains U.K. MHRA approval for phase I study of TG-4050 for head and neck cancer

STAT3 could be a novel target for treating endometriosis

BioMarck reports phase II data on BIO-11006 in NSCLC

Radiolabeled GRP-R antagonist [177Lu]RM-2 evaluated in advanced prostate cancer patients

Regeneron studies REGN-5713-5714-5715 in healthy adults and subjects with birch pollen allergy

Novel collagen-targeted PET tracer: safety, distribution and detection of collagen deposition in IPF

Organotrifluoroborate as a theranostic synthon for PET imaging-guided BNCT

Preclinical and first-in-human studies of [18F]DASA-23, a radiopharmaceutical for glioblastoma

SO-C101 begins first-in-human study in advanced/metastatic solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...